MaxCyte Reports 15% Revenue Decline in FY25, Issues Lower 2026 Guidance Amid Customer Headwinds
MXCT is trading near its 52-week low of $0.643 (9.0% above the low).
Summary
MaxCyte reported a 15% decline in full-year 2025 revenue to $33.0 million and provided 2026 revenue guidance of $30-32 million, which is below the 2025 actuals. The company cited headwinds from select Strategic Platform License (SPL) customers, including a 15% reduction from its largest customer, impacting both 2025 results and 2026 projections. This negative financial performance and outlook are highly material, especially following the recent Nasdaq non-compliance notice regarding its sub-$1.00 stock price. While the company maintains a strong cash position of $155.6 million, the continued revenue contraction and lower guidance will likely put further pressure on the stock as it navigates its delisting challenge. Traders will be watching for signs of stabilization in SPL customer activity and the impact of new product launches on core revenue growth.
At the time of this announcement, MXCT was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.9M. The 52-week trading range was $0.64 to $3.17. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.